MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/annrheumdis-2018-215004

Медицинская библиотека · Annals of the rheumatic diseases · 2019

Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis.

Sabbagh Sara, Pinal-Fernandez Iago, Kishi Takayuki, Targoff Ira N, Miller Frederick W, Rider Lisa G, Mammen Andrew Lee, Childhood Myositis Heterogeneity Collaborative Study Group

СтатьяПоддержка NIH: внешняя программаResearch Support, N.I.H., IntramuralПеревод в очереди

Аннотация

OBJECTIVES

Anti-Ro52 autoantibodies are associated with more severe interstitial lung disease (ILD) in adult myositis patients with antiaminoacyl transfer (t)RNA synthetase autoantibodies. However, few studies have examined anti-Ro52 autoantibodies in juvenile myositis. The purpose of this study was to define the prevalence and clinical features associated with anti-Ro52 autoantibodies in a large cohort of patients with juvenile myositis.

METHODS

We screened sera from 302 patients with juvenile dermatomyositis (JDM), 25 patients with juvenile polymyositis (JPM) and 44 patients with juvenile connective tissue disease-myositis overlap (JCTM) for anti-Ro52 autoantibodies by ELISA. Clinical characteristics were compared between myositis patients with and without anti-Ro52 autoantibodies.

RESULTS

Anti-Ro52 autoantibodies were found in 14% patients with JDM, 12% with JPM and 18% with JCTM. Anti-Ro52 autoantibodies were more frequent in patients with antiaminoacyl tRNA synthetase (64%, p<0.001) and anti-MDA5 (31%, p<0.05) autoantibodies. After controlling for the presence of myositis-specific autoantibodies, anti-Ro52 autoantibodies were associated with the presence of ILD (36% vs 4%, p<0.001). Disease course was more frequently chronic, remission was less common, and an increased number of medications was received in anti-Ro52 positive patients.

CONCLUSIONS

Anti-Ro52 autoantibodies are present in 14% of patients with juvenile myositis and are strongly associated with anti-MDA5 and antiaminoacyl tRNA synthetase autoantibodies. In all patients with juvenile myositis, those with anti-Ro52 autoantibodies were more likely to have ILD. Furthermore, patients with anti-Ro52 autoantibodies have more severe disease and a poorer prognosis.

Для цитирования: Sabbagh Sara, Pinal-Fernandez Iago, Kishi Takayuki, Targoff Ira N, Miller Frederick W, Rider Lisa G, Mammen Andrew Lee, Childhood Myositis Heterogeneity Collaborative Study Group. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis.. Annals of the rheumatic diseases. 2019. DOI: 10.1136/annrheumdis-2018-215004.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.